Literature DB >> 16118470

Interactions between tricyclic antidepressants and phospholipid bilayer membranes.

Z Fisar1.   

Abstract

Participation of electrostatic and other noncovalent interactions in the binding of tricyclic antidepressants (TCAs) to the lipid bilayers was estimated from pH-dependencies of imipramine, desipramine, amitriptyline and nortriptyline binding to the lipid bilayers prepared from different phospholipids, both electroneutral and acidic. The binding was studied using a radioligand binding assay. It was found that the membrane phospholipid composition and methylation of the acyl side chain of TCA has a decisive effect on participation of particular noncovalent interactions in the binding. Apparent high-affinity binding of TCAs to the phosphatidylcholine or phosphatidylethanolamine membranes are achieved mainly by incorporation of uncharged drug molecules into the hydrophobic core of the bilayers. Van der Waals forces and hydrophobic effect are responsible for this binding. Both charged and uncharged drug molecules bind to phosphatidylserine membranes, therefore coulomb- or ion-induced dipole interactions play a role in these binding. Different spatial distribution of charged residues within the interface causes different electrostatic interactions between charged TCAs and vesicles formed from phosphatidylserine and phosphatidylinositol. The data supports the hypothesis under which TCAs could have effect on affective disorders partially via binding to the lipid part of the membrane and following changes of lipid-protein interactions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16118470

Source DB:  PubMed          Journal:  Gen Physiol Biophys        ISSN: 0231-5882            Impact factor:   1.512


  9 in total

Review 1.  Brain tissue lipidomics: direct probing using matrix-assisted laser desorption/ionization mass spectrometry.

Authors:  Amina S Woods; Shelley N Jackson
Journal:  AAPS J       Date:  2006-06-02       Impact factor: 4.009

Review 2.  Focus on fatty acids in the neurometabolic pathophysiology of psychiatric disorders.

Authors:  R J T Mocking; J Assies; H G Ruhé; A H Schene
Journal:  J Inherit Metab Dis       Date:  2018-03-09       Impact factor: 4.982

Review 3.  Drug-Induced Mitochondrial Toxicity.

Authors:  Iain P Hargreaves; Mesfer Al Shahrani; Luke Wainwright; Simon J R Heales
Journal:  Drug Saf       Date:  2016-07       Impact factor: 5.606

Review 4.  Mechanistic review of drug-induced steatohepatitis.

Authors:  Justin D Schumacher; Grace L Guo
Journal:  Toxicol Appl Pharmacol       Date:  2015-09-05       Impact factor: 4.219

5.  Antidepressants are modifiers of lipid bilayer properties.

Authors:  Ruchi Kapoor; Thasin A Peyear; Roger E Koeppe; Olaf S Andersen
Journal:  J Gen Physiol       Date:  2019-02-22       Impact factor: 4.086

6.  Effect of Selected Anionic and Cationic Drugs Affecting the Central Nervous System on Electrical Properties of Phosphatidylcholine Liposomes: Experiment and Theory.

Authors:  Joanna Kotyńska; Monika Naumowicz
Journal:  Int J Mol Sci       Date:  2021-02-25       Impact factor: 5.923

7.  Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder.

Authors:  R J T Mocking; I Harmsen; J Assies; M W J Koeter; H G Ruhé; A H Schene
Journal:  Transl Psychiatry       Date:  2016-03-15       Impact factor: 6.222

8.  Imipramine alters the sterol profile in Leishmania amazonensis and increases its sensitivity to miconazole.

Authors:  Valter Viana Andrade-Neto; Thaís Martins Pereira; Marilene do Canto-Cavalheiro; Eduardo Caio Torres-Santos
Journal:  Parasit Vectors       Date:  2016-03-31       Impact factor: 3.876

9.  The Effect of Dextran Sulfate-as Model Glycosaminoglycan Analogue-on Membrane Lipids: DPPC, Cholesterol, and DPPC-Cholesterol Mixture. The Monolayer Study.

Authors:  Katarzyna Makyła-Juzak; Anna Chachaj-Brekiesz; Patrycja Dynarowicz-Latka; Paweł Dąbczyński; Joanna Zemla
Journal:  J Membr Biol       Date:  2018-07-20       Impact factor: 1.843

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.